25563-02-4

Usage

Uses

Used in Pharmaceutical Industry:
2-Phenoxyphenylacetic acid is used as a key intermediate in the synthesis of various pharmaceuticals. Its unique chemical structure allows for the development of new drugs with potential therapeutic applications.
Used in Agrochemical Industry:
In the agrochemical industry, 2-Phenoxyphenylacetic acid serves as a precursor for the production of agrochemicals, such as herbicides and pesticides. Its incorporation into these products can enhance their effectiveness in controlling pests and weeds.
Used in Organic Chemistry Research:
As a commonly used reagent in organic chemistry research, 2-Phenoxyphenylacetic acid is employed in various chemical reactions to explore its properties and potential applications. Its versatility as a building block enables the synthesis of new organic compounds with diverse functionalities.
Used in Material Science:
2-Phenoxyphenylacetic acid has potential applications in the field of material science, particularly for the production of polymers and other advanced materials. Its unique chemical structure can contribute to the development of materials with improved properties, such as enhanced strength, flexibility, or thermal stability.
Used in Anti-Inflammatory Applications:
Due to its anti-inflammatory properties, 2-Phenoxyphenylacetic acid can be used as a therapeutic agent for the treatment of various inflammatory conditions. Its ability to modulate inflammatory pathways may provide relief from symptoms and promote healing in affected tissues.

InChI:InChI=1/C14H12O3/c15-14(16)10-11-6-4-5-9-13(11)17-12-7-2-1-3-8-12/h1-9H,10H2,(H,15,16)

Upstream product

• 81851-92-5 1-morpholino-2-(o-phenoxyphenyl)-1-ethanethione 
• 64-19-7 acetic acid 
• 77963-52-1 (2-phenoxy-phenyl)-pyruvic acid 
• 26388-13-6 1-(2-phenoxyphenyl)ethan-1-one 
• 103474-02-8 methyl 2-(2-phenoxyphenyl)acetate 
• 5888-53-9 2-phenoxybenzyl chloride 
• 88-67-5 2-Iodobenzoic acid 
• 41755-76-4 ethyl 2-phenoxybenzoate 
• 108-86-1 bromobenzene 
• 108-95-2 phenol 
• 446-52-6 2-Fluorobenzaldehyde 
• 108-90-7 chlorobenzene 
• 33838-32-3 potassium 2-formylphenolate 
• 19434-34-5 2-(phenoxy)benzaldehyde 

Downstream Products

• 61447-89-0 4,6-bis(4-methylpent-3-en-1-yl)-6-methylcyclohexa-1,3-diene-1-carbaldehyde 
• 103474-02-8 methyl 2-(2-phenoxyphenyl)acetate 
• 1417512-55-0 ethyl 2-(2-phenoxyphenyl)acetate 
• 1580001-09-7 5-(2-phenoxybenzyl)-2H-1,2,4-triazole-3(4H)-thione 
• 1580001-12-2 5-(2-phenoxybenzyl)-3-methylthio-4H-1,2,4-triazole 
• 1580001-14-4 5-(2-phenoxybenzyl)-3-ethylthio-4H-1,2,4-triazole 
• 1580001-15-5 5-(2-phenoxybenzyl)-3-propylthio-4H-1,2,4-triazole 
• 1580001-16-6 5-(2-phenoxybenzyl)-3-benzylthio-4H-1,2,4-triazole 
• 159731-09-6 2-(2-phenoxyphenyl)acetic acid hydrazide 
• 1580001-29-1 2-amino-5-(2-phenoxybenzyl)-1,3,4-oxadiazole 
• 1580001-32-6 5-ethoxy-3-(2-phenoxybenzyl)-4H-1,2,4-triazole 
• 1030829-49-2 2-(2-phenoxyphenyl)ethan-1-ol 
• 1173289-44-5 N-(4-hydroxyphenethyl)-2-(2-phenoxyphenyl)acetamide 
• 73236-56-3 [2-(10,11-Dihydro-dibenzo[b,f]oxepin-10-ylsulfanyl)-ethyl]-phenethyl-amine 

Relevant academic research and scientific papers

MALIC ENZYME INHIBITORS

The present invention relates to novel compounds useful as malic enzyme (ME) inhibitors, processes for their preparation and use of these compounds for the therapeutic treatment of disorders mediated by ME such as cancers (e.g. pancreatic ductal adenocarcinoma (PDAC)) in humans.

HETEROCYCLIC COMPOUND AND ORGANIC LIGHT EMITTING DEVICE COMPRISING THE SAME

Provided in the present invention are a heterocyclic compound and an organic light emitting device comprising the same. Provided in the present invention is a heterocyclic compound presented by following chemical formula 1. The heterocyclic compound according to embodiments of the present invention has a proper energy level, and has excellent electrochemical stability and thermal stability. Therefore, an organic light emitting device including the compound provides high efficiency and/or high driving stability.

Synthesis of targeted dibenzo[b,f]thiepines and dibenzo[b,f]oxepines as potential lead molecules with promising anti-breast cancer activity

A targeted library of substituted dibenzo[b,f]thiepines and dibenzo[b,f]oxepines (prototypes I, II and III), and structurally analogous to tamoxifen have been synthesized as a new class of anti-breast cancer agents. All the prototype molecules exhibited potential antiproliferative activity against ER + ve and ER-ve breast cancer cell lines. Dibenzo[b,f]thiepine prototypes were found to be more active. Of all the compound tested, 14b exhibited potent in-vitro antiproliferative activity at 1.33 μM and 5 μM concentration in MCF-7 and MDA-MB-231 cell lines and was devoid of any cytotoxicity in normal HEK cells even at 50 μM. Cell cycle analysis showed that the compound 14b inhibited cell proliferation due to G0/G1 arrest in MCF-7 cells. Annexin-V FITC and PI staining experiments confirmed that the cell inhibition was primarily due to apoptosis and not by necrosis, which was also supported by LDH release assay experiment. Molecular docking studies showed better binding interaction of the new dibenzo[b,f]thiepine analogue 14b with the estrogen receptor (ER) as compared to 4-hydroxy-tamoxifen and this enhanced binding might be responsible for its estrogen antagonistic activity that induces cell cycle arrest, apoptosis and inhibition of breast cancer cells.

Synthesis, receptor affinity and effect on pentylenetetrazole-induced seizure threshold of novel benzodiazepine analogues: 3-Substituted 5-(2-phenoxybenzyl)-4H-1,2,4-triazoles and 2-amino-5-(phenoxybenzyl)-1,3,4- oxadiazoles

The new series of 5-(2-phenoxybenzyl)-4H-1,2,4-triazoles, possessing C-3 thio, alkylthio and ethoxy substituents, and 2-amino-5-(2-phenoxybenzyl)-1,3,4- oxadiazoles were designed and synthesized as novel benzodiazepine analogues. Most of them revealed sim

Synthesis of the Polycyclic Ring Systems of Artocarpol A and D

(Equation Presented) The first synthesis of the polycyclic ring systems of artocarpol A and D has been accomplished. These natural products were isolated recently from the root bark of Artocarpus rigida, and artocarpol A has been shown to have potent anti

Substituted (2-Phenoxyphenyl)acetic Acids with Antiinflammatory Activity. 1

The synthesis and antiinflammatory activity of a series of substituted (2-phenoxyphenyl)acetic acids are described.Initial screening in the adjuvant arthritis test showed that halogen substitution in the phenoxy ring enhanced activity considerably.Ulcerogenic potential, as measured by the minimum ulcerogenic dose (MUD), was low in almost all the acids tested. acetic acid possessed the most favorable combination of potency with low toxicity, including ulcerogenicity, and this compound is now in therapeutic use.

Affinity of 10-(4-Methylpiperazino)dibenzoxepins for Clozapine and Spiroperidol Binding Sites in Rat Brain

10-(4-Methylpiperazino)dibenzoxepins were prepared and evaluated as potential antipsychotic agents using specific clozapine diazepine> binding sites in rat forebrain that are noncholinergic and nondopaminergic in nature and from which clozapine is displaced by known antipsychotic agents. Clozapine binding in the presence of atropine represents nonmuscarinic binding, while binding in the absence of atropine represents muscarinic (cholinergic) plus nonmuscarinic binding.The relative affinity for dopamine binding sites was determined by displacement of spiroperidol from binding sites in rat caudate nuclei.Thus, clozapine, its 2-chloro isomer, its dechloro analogue, and their 5H-dibenzocycloheptene and dibenzoxepin analogues have about the same relative affinity for the nonmuscarinic clozapine binding sites.At the spiroperidol (dopaminergic) sites, both the nature of the tricyclic system and the presence of chlorine atom on the tricyclic system have a substantial effect on the binding affinity.Within each series, shift of a chlorine atom from the position distal to the piperazino group to the proximal position increases the binding affinity by a factor of about nine, but removal of the chlorine atom substantially decreases the binding affinity.Nevertheless, 10-(4-methylpiperazino)dibenzoxepin has a threefold greater affinity for the dopaminergic binding sites than does clozapine itself.